Summary.-The i.v. injection of high doses (3 mg) of BCG into C3H mice bearing a transplantable 3-methylcholanthrene-induced fibrosarcoma caused the regression of a significant proportion. This effect was most evident when the BCG was injected on the day of the graft, or 7 days later. The injection of this agent either 14 days before the graft, or in low doses (0.1 or 0 5 mg), or directly into the tumour (i.t.) only prolonged the survival of the animals. Spleen cells from systemic high-dose BCGtreated mice were found to exert a strong nonspecific cytostatic effect in vitro that was not an artefact of the test conditions, and was not expressed by cells from lowdose animals. The cytostatic effect was shown to be caused by cells with the characteristics of macrophages, i.e. they were strongly adherent, unaffected by treatment with anti-Thy 1.2 + C', radioresistant but heat-sensitive, and were detected in BCG-treated "B" mice.
in BCG-treated "B" mice.
The spleens of high-dose BCG-treated mice also contained suppressor cells that were capable of inhibiting the in vitro reactivity of normal T cells to PHA. Like the cytostatic effect, this suppressor activity was not detected in low-dose mice, and the cells responsible had the properties of macrophages; the effect was lost after the removal of adherent cells by sequential exposure to plastic and colloidal iron, but was conserved after treatment with anti-Thy 1.2 + C'. T-cell-deprived animals, such as "B" or nude mice, also developed suppressor-cell activity when treated with systemic high-dose BCG. Close parallels became evident between the in vivo anti-tumour activity of BCG, the in vitro cytostatic effect, and the suppressor-cell activity. We here discuss the possible role of suppressor cells in the mechanism of action of this agent.
A MAJOR ADVANCE in the field of immunology during the past few years has been the concept that immune reactions are controlled by negative feed-back mechanisms through suppressor cells (Gershon & Kondo, 1971) . In many immunological model systems suppressor cells of different types, particularly suppressor T cells (Ha et al., 1974) , but also B cells (Zembala et al., 1976) and macrophages (Nelson, 1976) , have been implicated. There have been a number of reports that suppressor cells may also play a role in the immunosuppression found in some experimental tumour models (Greene et al., 1977) . In this respect, various bacterial vaccines such as BCG have been demonstrated to enhance nonspecifically a number of immune responses (Miller et al., 1973) and are reported to produce a clinical improvement in some cases of leukaemia (Mathe et al., 1974) and melanoma (Morton et al., 1970) . Also in various animal models, like the one described in this report, BCGr treatment can exert a marked curative effect (Hanna et al., 1972 Poupon, 1978) BCG "Immuno BCG", which retains 950o viability after 3 months storage at 4°C, wvas kindly provided by the Pasteur Institute (Paris, France) and injected as described in the results. High doses (3 mg) i.v. caused marked splenomegaly and hepatomegaly, viz., spleen weights of 180 and 450 mg on Days 7 and 14 respectively, and liver wNeights of 1-6 and 2-6 g on these days (controls: 95 mg and 1P3 g respectively).
Cell preparations Spleen, cells. Spleens from groups of 4 mice wvere aseptically removed, placed in Medium 199 (Eurobio, France) and gently squeezed between 2 sterile glass slides. The cell suspensions thus obtained wvere then filtered through gauze and washed wvith cold sterile Medium 199. For subsequent tests the suspensions wvere prepared in RPMI 1640 (Eurobio, France) supplemented wvith 2mM glutamine (Gibco, Grand Island, New-York) and containing 500 fresh human AB serum (decomplemented by heating at 56°C for 30 min), 100 i.u./ml penicillin and 100 ,Lg/ml streptomycin. When irradiated, the cells received 15 Gy delivered by a caesium bomb (Gravaton Industries, Gosport, Hampshire).
Enriched T cells. T cells wvere isolated with nylon w-ool columns using the technique of Julius et al. (1973) . Anti-Thy 1.2 serumn (Lespinats & Poupon, 1977) Table I , presenting the results of one of our experiments, it can be seen that all the untreated animals died about 35 days after grafting. When 3 mg BCG was injected on Day -14, only 2/7 of the tumours were rejected. Although this proportion was not statistically significant, the survival of the animals that died was significantly lengthened. When the high dose of BCG was injected on Day 0, 5/7 animals survived, this proportion being statistically significant, and the mean time of death of the remainder was considerably delayed. The injection of 3 mg BCG on Day 7 caused both a significant tumour rejection (5/10) and an increase in survival time of the mice that died. Low doses of BCG on Day 0 (0 1 mg) or Day 7 (0.5 mg) had no curative effect, though they did prolong life. It is of interest to note that when 1-5 mg of BCG was injected twice, with an interval of 7 days, into small growing tumours about 10 days after grafting (diameter 5 mm), there was no rejection in 9 mice, though the mean survival time was increased. This cytotoxicity was also tested for its sensitivity to irradiation (15 Gy) or heating (56°C, 30 min). Table II presents the results of 4 representative experiments, in which it can be seen (Exp. 1) that whole spleen-cell preparations from high-dose BCG animals inhibited the DNA synthesis of tumour cells with which they were co-cultivated in vitro.
This cytostatic effect was also exerted by the adherent cells from such populations, and treatment with anti-Thy 1.2+ C' did not diminish their activity (Exp. 2).
It can also be seen (Exp. 3) that the spleen cells from high-dose BCG-treated "B" mice were cytostatic to the growth of McB6-1 tumour cells.
In contrast to these results, cells from low-dose BCG animals had no significant effect in these tests (Exp. 4).
The figure demonstrates that In the light of the previous results, it was thought important to determine whether in fact T cells were necessary for the generation or expression of the suppressive effect on PHA responsiveness.
In Table IV 
DISCUSSION
An anti-tumour effect of BCG in experimental animal models has often been reported (Hanna et al., 1972) , but in many systems this effect is prophylactic rather than therapeutic (Finklestein et al., 1972) . When, however, therapeutic effects were found against solid tumours, it was usually necessary also to inject the BCG directly into the lesion (Hanna et al., 1972) . In our experiments with a solid transplantable :3-methylcholanthrene-induced fibrosarcoma of C3H mice, a significant antitumour effect was found when high doses of BCG were injected systemically at the same time as, or 7 days after, the graft. This protection was expressed as a significant proportion of the animals controlling and subsequently rejecting their tumours. Even the animals that died survived longer. In this model, high-dose systemic BCG exerted much less antitumour activity when applied prophylactically. Also, the intra-tumoural injection of BCG exerted very little protection, detectable only as a lengthened survival time after grafting. The fact that BCG administered systemically exerted an effect in this model, but not in many others, may be explained by the requirement for a high dose (3 mg); lower doses (0.1 or 0 5 mg) that are commonly used had no curative effects, though they did increase survival times. It is of interest to note here that animals that had rejected their tumour grafts after BCG treatment were resistant to further challenge grafts, whereas only about half of the animals that had been surgically cured of their tumour rejected a second graft, (results not presented). This observation can be interpreted to mean that high-dose systemic BCG activates the immune mechanism, or at least allows longer and more effective contact of the animal with the tumour antigens.
We decided, however, to examine in more detail nonspecific mechanisms that might contribute to BCG-stimulated tumour control. Considering the well documented effect of BCG on the reticuloendothelial system (Hibbs, 1975) we evaluated more precisely the role of the macrophage.
We chose a cytostatic assay to examine any nonspecific in vitro anti-tumour effects of high-dose systemic BCG, and also studied the suppressive effect of spleen cells from such animals on T-cell PHA response. We found that spleen cells from animals treated systemically with high (but not low) doses of BCG greatly inhibited the proliferation of cultured fibrosarcoma cells and PHA-stimulated lymphoid cells. The cells responsible were found to be strongly adherent to plastic, and the activity was removed by the sequential exposure of the spleen cell population to plastic and colloidal iron. In earlier studies (Orbach-Arbouys & Poupon, 1978) it was reported that, in addition to the adherent fraction, suppressive and cytostatic activities were found in T-cell populations that had been prepared by passage through nylon-wool columns. In the present study, however, we demonstrated that only 75%o of such preparations expressed the surface markers of T cells, in contrast to 9400 in cell populations obtained from normal animals. The apparent contamination of the former may represent T cells that were not expressing Thy-1.2 anitigen due to their stage of proliferation or differentiation, or non-T cells that were weakly adherent for similar reasons. We found that the cytostatic and suppressive activities were not affected by treatment with anti-Thy 1.2+ C', were not sensitive to irradiation, but were lost upon heating. Confirmation of the non-Tcell character of the cells responsible, and their independence of a functional thymus, was obtained by our studies of BCGtreated "B" or nude mice.
The cytostatic and suppressive cells have, therefore, the properties of macro-phages. Similar results have been reported in other systems (Klimpel & Henney, 1978) though the i.v. route of BCG injection has been suggested as ineffective (Germain et al., 1975 (Scott, 1974) , while the injection of high doses is largely suppressive, small doses are predominantly stimulatory for a variety of responses.
The T-cell independence of these activities is most important, as Mackaness (1 970) and Evans & Alexander (1972) propose as a mechanism the following scheme: T cells specific for the antigens of BCG, upon reaction with these, secrete mediators (lymphokines) that provoke the activation of monocytes and macrophages, which are then cytostatic. Our results suggest, however, a more direct influence of BCGon the macrophage. It should also be noted here that in various acute infections suppressive activity appears to be due to either T cells or macrophages, but not both together (Jones et al., 1976; Bullock et al., 1978; Scott, 1974) .
It is of considerable importance to discuss a problem related to the technique of the cytostatic and suppressive assays used in our studies. Waldman & Gottlieb (1973) have presented evidence that macrophages are able to secrete a factor that apparently inhibits mitosis, and Badger et al. (1973) have described a factor with similar effects secreted by mitogen-stimulated lymphocytes. Calderon et al. (1974) and Stadecker et al. (1977) The fact that significant in vivo and in vitro anti-tumour activities were always paralleled by the generation of nonspecific suppressor-cell activity in our system poses the question of the involvement of the latter cells in these mechanisms. In effect, considerable uncertainty surrounds the role of immune responses, specific or not, in the control of tumour growth. This probably arises largely from the great complexity of the host-tumour relationship, and the participation of numerous effector and suppressor systems. Considerable information exists in the literature on the effect of suppressor cells on antitumour responses. Anergy, or immunodeficiency, have been associated with the development of suppressor cells in neoplasias such as myelomas (Broder et al., 1975) or Hodgkin's disease (Twomey et al., 1975 ). It appears, however, that when the suppression is specific, suppressor T cells can be demonstrated. As the injection of BCG causes the development of nonspecific suppressor cells, probably macrophages, it is reasonable to postulate that the effects on the host-tumour relationship might be 836 N. CASTES, N. R. LYNCH, G. LESPINATS AND S. ORBACH-ARBOUYS different. Some evidence does, in fact, implicate suppressor cells in tumour control. For example, the existence of nonspecific concomitant immunity to the growth of a tumour different from the primary ( Van der G(aarg & McCullagh, 1978) may be due to tumour-induced suppressor cells. It has also been reported that adherent macrophage-like cells that can inhibit lymphocyte response to mitogens can be correlated with a better prognosis in human cancer (Mikulski & Muggia, 1978) , and that cytotoxic T cells appear to be most effective when in a non-dividing state (Cantor & Jandinski, 1974) . It can therefore be suggested that a suppressive activity, that is most conveniently measured by inhibition of mitogen response, may be of great importance on account of its capacity to interfere with the proliferation of a number of cell types, lymphoid or tumoral. In such a case, chemotherapy protocols that are designed to diminish suppressor-cell activity (Orbach-Arbouys & Castes, 1979) and studies using mitogen response as an indicator of the "immunocompetence" of cancer patients (Mekori et al., 1974) should be evaluated with care. A notable lack of correspondence between the anti-tumour effects of indomethacin and activation of depressed mitogen response for example, has been reported, and severely depressed mitogen response does not necessarily mean the existence of a general state of immune depression (Lynch et al., 1978) . It is obvious that the generation of suppressor cells could be disadvantageous to the host if they limited specific immune response, though considering the possible "blocking" activity of antibody, a preferential expression of nonspecific mechanisms may aid in tumour control. It can be suggested that excessive production of suppressor cells, such as might occur when tumours are particularly large (Poupon et al., 1976) or when very high doses of BCG are injected (Olsson et al., 1978) , might facilitate tumouir growth.
In conclusion, we can coinsider 3 possible mnechanisms by which BCG-induced suppressor cells could be involved in tumour control. One is that the suppressor cells are generated in parallel with the actual effector cells, and might regulate, positively or negatively, the activity of such cells. A second possibility is that the suppressor cells are precursors of the effector cells, and a third is that the suppressor cells are actually a population of anti-tumour effector cells. Considering the parallels that we have found between the suppressor cell and anti-tumour activities, we favour the third possibility. Thus the activity of these cells, though detected as an in vitro suppression of various responses, may be an important mechanism of tumour control.
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